Treatment for late-onset obsessive-compulsive disorder with Parkinsonism

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 20, Issue 3, 2008, Pages 331-336

  Agarwal, Arunlata ^a,c   Biswas, Devdutta ^a   Sadhu, Raja ^b  

^a G B PANT HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; MIANSERIN; MIRTAZAPINE; RISPERIDONE; VALPROIC ACID; VENLAFAXINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; DEPRESSION; DRUG CHOICE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; OBSESSIVE COMPULSIVE DISORDER; ONSET AGE; PANIC; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; UNSPECIFIED SIDE EFFECT;

EID: 52649152393     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2008.20.3.331     Document Type: Article

References (42)

1. Maia AF, Barbosa ER, Menezes PR: Relationship between obsessive compulsive disorders and diseases affecting primarily the basal ganglia. Rev Hosp Clin Fac Med S Paulo 1999; 54:213-221
2. Cheyette SR, Cummings J: Encephalitis lethargica: lessons for contemporary neuropsychiatry. J Neuropsychiatry Clin Neurosci 1995; 7:125-134
3. Schilder P: The organic background of obsessions and compulsions. Am J Psychiatry 1938; 94:1397-1413
4. Carsen S, Xia C: Editorial. McGill J Med 2006; 9:80-81
5. Baxter LR, Phelps ME, Mazziotta JC, et al: Local cerebral glucose metabolic rates in obsessive-compulsive disorder: a comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry 1987; 44:211-218
6. Baxter LR, Schwartz JM, Mazziotta JC, et al: Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry 1988; 145:1560-1563
7. Luxenberg JS, Swedo SE, Flament MF: Neuroanatomical abnormalities in obsessive-compulsive disorder detected with quantitative x-ray computed tomography. Am J Psychiatry 1988; 145:1089-1093
8. Robinson D, Wu H, Munne RA, et al: Reduced caudate nucleus volume in obsessive-compulsive disorder. Arch Gen Psychiatry 1995; 52:393-398
9. Pujol J, Soriano-Mas C, Alonso P, et al: Mapping structural brain alterations in obsessive-compulsive disorder. Arch Gen Psychiatry 2004; 61:720-730
10. Baxter LR, Schwartz JM, Bergman KS: Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49:681-689
11. Model JG, Mountz JM, Cortis GC: Neurophysiologic dysfunction in basal ganglia/limbic striatal and thalamocortical circuits as a pathogenetic mechanism of obsessive compulsive disorder. J Neuropsychiatry Clin Neurosci 1989; 1:27-36
12. Graybiel AM, Rauch SL: Toward a neurobiology of obsessive-compulsive disorder. Neuron 2000; 28:343-347
13. Laplane D, Levasseur M, Pillon B, et al: Obsessive-compulsive and other behavioral changes with bilateral basal ganglia lesions. Brain 1989; 112:699-725
14. Weilburg JB, Mesulam MM, Weintraub S: Focal striatal abnormalities in a patient with obsessive-compulsive disorder. Arch Neurol 1989; 46:233-235
15. Croisile B, Tourniaire D, Confavreux C, et al: Bilateral damage to the head of the caudate nuclei. Ann Neurol 1989; 25: 313-314
16. Ward C: Transient feelings of compulsion caused by hemispheric lesion: 3 cases. J Neurol Neurosurg Psychiatry 1988; 51:266-268
17. Lopez-Rodriguez F, Gunay I, Glaser N: Obsessive compulsive disorder in a woman with left basal ganglia infarct: a case report. Behavioral Neurology 1997; 10:101-103
18. Williams AC, Owen C, Heath DA: A compulsive movement disorder with cavitation of the caudate nucleus. J Neurol Neurosurg Psychiatry 1998; 51:447-448
19. Chacko RC, Corbin MA, Harper RG: Acquired obsessive-compulsive disorder associated with basal ganglia lesions. J Neuropsychiatry Clin Neurosci 2000; 12:269-272
20. Weiss AP, Jenike MA: Late onset obsessive-compulsive disorder: a case series. J Neuropsychiatry Clin Neurosci 2000; 12:265-268
21. Stein MB, Heuser IJ, Juncos JL, et al: Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 1990; 147:217-220
22. Lauterbach EC, Duvoisin RC: Anxiety disorders in familial parkinsonism (letter). Am J Psychiatry 1991; 148:274
23. Richard IH, Schiffer RB, Kurian R: Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci 1996; 8:383-392
24. Tomer R, Levin BE, Weiner WJ: Obsessive-compulsive symptoms and motor asymmetries in Parkinson's disease. Neuropsych Neuropsychol Behav Neurol 1993; 6:26-30
25. Muller N, Putz A, Kathmann N, et al: Characteristics of obsessive-compulsive symptoms in Tourette's syndrome, obsessive-compulsive disorder and Parkinson's disease. Psychiatry Res 1997; 70:105-114
26. Alegret M, Junque C, Vallderiola F: Obsessive-compulsive symptoms in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001; 70:394-396
27. Maia AF, Barbosa ER, Menezes PR: Obsessive-compulsive symptoms, obsessive-compulsive disorder and related disorders in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2003; 15:371-374
28. Chouinard G, Sultan S: A case of Parkinson's disease exacerbated by fluoxetine. Human Psychopharmacol 1992; 7:63-66
29. Steur EN: Increase of Parkinson disability after fluoxetine medication. Neurology 1993; 43: 211-213
30. Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquera G: Parkinsonism exacerbated by paroxetine. Neurology 1994; 44:2406
31. Richard IH, Kurian R: A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology 1997; 49:1168-1170
32. van de Vijver DA, Roos RA, Jansen PA: Start of SSRI and increase in antiparkinsonian drug treatment in patients on L-dopa. Br J Clin Pharmacol 2002; 54:168-170
33. Avila A, Cardona X, Maho P, et al: Does nefazodone improve both depression and Parkinson's disease? A pilot randomized trial. J Clin Psychopharmacology 2003; 23:509-513
34. Cools R, Barker RA: L-Dopa increases impulsivity in patients with Parkinson's disease. Neuropsychologia 2003; 41:1431-1441
35. Pontone G, Williams JR, Bassett SS, et al: Clinical features associated with impulse control disorders in Parkinson's disease. Neurology 2006; 67:1258-1261
36. Voon V, Hassan K, Zurowski M, et al: Prevalence of repetitive and reward seeking behaviors in Parkinson's disease. Neurology 2006; 67:1254-1257
37. Laitinen L: Desipramine in treatment of Parkinson's disease: a placebo controlled study. Acta Neurol Scand 1969; 45:109-113
38. Andersen J, Aabro E, Gulmann N: Antidepressant treatment in Parkinson's disease: a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurol Scand 1980; 62:210-219
39. Klaassen T, Verhey FR, Sneijders GH: Treatment of depression in Parkinson's disease: a meta-analysis. J Neuropsychiatry Clin Neurosci 1995; 7:281-286
40. Vaida FJ, Solinas C: Current approaches to management of depression in Parkinson's disease. J Clin Neurosci 2005; 12:739-743
41. Goodman WK, Price LH, Rasmussen SA: The Yale-Brown Obsessive Compulsive scale, part 1: development, use, and reliability. Arch Gen Psychiatry 1989; 46:1006-1011
42. Webster DD: Critical analysis of the disability in Parkinson's disease. Mod Treat 1968; 5:257-282